Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
08/2003
08/07/2003WO2003063573A2 Method for treating diseases with omega interferon
08/07/2003WO2003048375B1 Hybrid glycosylated products and their production and use
08/07/2003WO2003030616A3 21132, a human g-protein coupled receptor family member and uses therefor
08/07/2003WO2003025000A3 Peptides capable of modulating immune response
08/07/2003WO2002068615A3 Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
08/07/2003WO2002068476A3 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders
08/07/2003WO2002066059A3 Agents that specifically block cd28-mediated signaling and uses therefor
08/07/2003WO2002056873A3 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002030259A9 Disease prevention by reactivation of the thymus
08/07/2003WO2002004015A9 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149266 Administering to a patient (a warm blooded animal, such as man) an effective amount of a pyrimidine derivative for treating cancer, cell proliferation, and inhibition of focal adhesion kinase effect
08/07/2003US20030149247 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
08/07/2003US20030149244 Adjusting affinity of Fab 27/26 fragments/polypeptides generating improved ragweed-induced histamine release inhibition; bronchodilator agents
08/07/2003US20030149242 Novel polypeptide
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149105 Suplatast tosilate crystals
08/07/2003US20030149083 For therapy of inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic erythematodes, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149057 Anti-cancer compounds
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149036 Substituted benzothiazole amide derivatives
08/07/2003US20030149026 For therapy of arthritis, fever, common cold, dysmenorrhea, menstrual cramps, inflammatory bowel disease, Crohn's disease, emphysema, acute respiratory distress syndrome, asthma, bronchitis, chronic obstructive pulmonary disease, etc.
08/07/2003US20030149011 Methods and reagents for extracorporeal immunomodulatory therapy
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149006 New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148990 Administering a therapeutically effective amount of an epidermal growth factor receptor (EGF-R) antagonist for therapy of hypersecretion of mucus in lungs
08/07/2003US20030148983 Polynucleotide therapy
08/07/2003US20030148981 Administering a therapeutic formulation containing the phosphorothioate oligonucleotide and at least one cyclodextrin to the mammal; monitoring the immune response of mammal
08/07/2003US20030148976 For therapy of cancer, infectious disease, and allergic disorders
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148949 Administering a trefoil peptide or biologically active fragment thereof to a skin lesion or region of the skin where a lesion is to be prevented; wound healing agents which can speed healing, reduce pain and delay/prevent lesions
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148945 Antimicrobial and anti-inflammatory peptides
08/07/2003US20030148938 Aqueous sustained-release formulations of proteins
08/07/2003US20030148517 Preparation and compositions for antrodia camphorata mycelium biologically active material
08/07/2003US20030148513 Preparing culture of pluripotent brain tissue for nervous tissue regeneration, tissue engineering and treating nervous system disorders
08/07/2003US20030148451 Endothelial differntiation gene 6-like g protein coupled receptor
08/07/2003US20030148446 Acute neuronal induced calcium binding protein type 1 ligand
08/07/2003US20030148312 Measuring the expression level of MAL gene; atopic dermatitis and bronchial asthma
08/07/2003US20030148285 Source of Immunodominant MHC-associated Peptides (SIMP); antibodies, probes, and cells, to characterize SIMP, modulate its cellular levels, diagnose and treat cancers and modulate immune response
08/07/2003US20030148262 Chimeric alphavirus replicon particles
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147923 Composition & corresponding method of using spores of bacillus subtilis to stimulate and/or enhance immune response in mammals
08/07/2003US20030147922 Vaccine against streptococcus pneumoniae capsular polysaccharides
08/07/2003US20030147905 Administering an oligopeptide for immunotherapy
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003US20030147902 Method of stimulating and immune response by administration of host organisms that express intimin alone of as a fusion protein with one of more other antigens
08/07/2003US20030147898 Adjuvant formulation comprising a submicron oil droplet emulson
08/07/2003US20030147889 Administering type 1-interferon antibody, for inhibition of prevention of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis
08/07/2003US20030147883 Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection
08/07/2003US20030147880 Genetic engineered nucleotide sequences codes a recombinant protein for treating allergy
08/07/2003US20030147865 Cell therapy using immunoregulatory T-cells
08/07/2003US20030147861 Compounds and methods for the modulation of immune responses
08/07/2003US20030147844 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials
08/07/2003CA2849427A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
08/07/2003CA2475003A1 Double-stranded oligonucleotides
08/07/2003CA2474910A1 Oligonucleotide compositions with enhanced efficiency
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474719A1 Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474571A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
08/07/2003CA2474277A1 2,4-pyrimidinediamine compounds and their uses
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473162A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2466228A1 Method for treating diseases with omega interferon
08/07/2003CA2463476A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
08/07/2003CA2443023A1 8-heteroaryl xanthine adenosine a2b receptor antagonists
08/06/2003EP1333274A2 Up-converting reporters for biological and other assays using laser excitation techniques
08/06/2003EP1333025A1 Cyanopyrrolidine derivatives
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332366A1 Methods for the treatment of cellular proliferative disorders
08/06/2003EP1332158A2 Peptides, the production and use thereof for binding immunoglobulins
08/06/2003EP1332151A1 Pyranoside derivatives
08/06/2003EP1332149A1 Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332132A2 Enamine derivatives as cell adhesion molecules
08/06/2003EP1332131A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332129A2 Acid derivatives useful as serine protease inhibitors
08/06/2003EP1332128A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP1331932A2 Therapeutic uses for ip 3? receptor-mediated calcium channel modulators
08/06/2003EP1187838B1 Thiazolopyrimidines useful as TNF-Alpha inhibitors
08/06/2003EP1165544B1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
08/06/2003EP1162945B1 Particle based vaccine composition
08/06/2003EP1140152B1 Method to produce inactivated w/o emulsion adjuvated vaccines
08/06/2003EP1117648B1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
08/06/2003EP1077684B1 Effervescent preparations
1 ... 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 ... 1172